Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LUNX ADC + EpCAM ADC + Trop-2 ADC + C-Met ADC
- Development stage
- Preclinical
- Lead developer
- Sinobioway
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LUNX ADC + EpCAM ADC + Trop-2 ADC + C-Met ADC refers to a portfolio of antibody-drug conjugate (ADC) programs under development by Anhui Sinobioway Medicine, a subsidiary of the Beijing Sinobioway Group. This program targets four distinct tumor-associated antigens: Lung-specific X protein (LUNX), Epithelial Cell Adhesion Molecule (EpCAM), Tumor-associated Calcium Signal Transducer 2 (Trop-2), and Hepatocyte Growth Factor Receptor (c-Met). These targets are frequently overexpressed in various malignancies, particularly non-small cell lung cancer (NSCLC) and other solid tumors. Each ADC in this group is designed to utilize the specificity of monoclonal antibodies to deliver potent cytotoxic agents directly to malignant cells, thereby enhancing therapeutic efficacy while reducing off-target systemic toxicity. These assets are currently in the early stages of development.
- Other names
- Sinobioway ADC programsLUNX-EpCAM-Trop-2-C-Met ADCLUNX-EpCAM-Trop2-C-Met ADCLUNX-EpCAM-Trop 2-C-Met ADC
02
Targets
BPIFA1 (BPI fold-containing family A member 1)EPCAM (Epithelial cell adhesion molecule)MET (Mesenchymal-epithelial transition factor receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on LUNX ADC + EpCAM ADC + Trop-2 ADC + C-Met ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUNX ADC + EpCAM ADC + Trop-2 ADC + C-Met ADC.